ストックスクリーナーアプリを入手
0.9468
2.02%
-0.0195
アフターアワーズ：
.97
0.0232
+2.45%
Jasper Therapeutics Inc (JSPR) 最新ニュース
Executive pay and board changes at Jasper Therapeutics (JSPR) - Stock Titan
Jasper Shares Surge Following Encouraging Early Asthma Trial Data - MSN
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN
Why UBS started Jasper Therapeutics (JSPR) at neutral despite progress in briquilimab - MSN
Acute Myeloid Leukemia Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharma, TC Biopharm - Barchart.com
Will Jasper Therapeutics (JSPR) Stock Fall Further | Price at $0.78, Up 10.73%Real Trader Insights - Newser
What is the biggest uncertainty for Jasper Therapeutics (JSPR) Stock | Price at $0.67, Up 0.87%Stop Loss Levels - Newser
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Insider Monkey
JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
12 Health Care Stocks Moving In Thursday's After-Market SessionBullfrog AI Hldgs (NASDAQ:BFRG), CDT Eq - Benzinga
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway - The Globe and Mail
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI - TipRanks
Citizens reiterates Jasper Therapeutics stock rating on CEO change By Investing.com - Investing.com Australia
Citizens reiterates Jasper Therapeutics stock rating on CEO change - Investing.com
Jasper Therapeutics stock gains 5% on clinical progress despite Q4 loss - Investing.com India
MINISO Group Holding Limited (MNSO) Reports Q4 Earnings - news.alphastreet.com
Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings - AlphaStreet
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - Bitget
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c) - TipRanks
Jasper Therapeutics (JSPR) 10-K focuses on briquilimab mast cell programs and funding needs - Stock Titan
JSPR: Strong clinical progress but increased net loss and lower cash reserves highlight funding needs - TradingView — Track All Markets
Jasper Therapeutics (NASDAQ: JSPR) posts $75.8M 2025 loss, cash at $28.7M - Stock Titan
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Jasper Therapeutics 4Q Loss $9.1M >JSPR - moomoo.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Jasper Therapeutics (JSPR) price target decreased by 30.92% to 8.92 - MSN
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $19.88 - Defense World
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab - Yahoo Finance
10 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
JSPR Stock Price, Quote & Chart | JASPER THERAPEUTICS INC (NASDAQ:JSPR) - ChartMill
Jasper Therapeutics Inc (JSPR) Stock News & Articles - 24/7 Wall St.
Jasper Therapeutics stock surges on positive briquilimab trial data amid mast cell therapy race - AD HOC NEWS
UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25 - marketscreener.com
UBS initiates Jasper Therapeutics stock rating at Neutral on competition By Investing.com - Investing.com Canada
1.77%
0.25%
大文字化:
|
ボリューム (24 時間):